Gastrin for the treatment of acute graft-versus-host disease of the stomach
Authors:
- Jana GawronJGJana Gawron
- Marie CzechMCMarie Czech
- Verena HolzmüllerVHVerena Holzmüller
- Grigor AndreevGAGrigor Andreev
- Ann-Cathrin BurkABAnn-Cathrin Burk
- Alina HartmannAHAlina Hartmann
- Sangya ChatterjeeSCSangya Chatterjee
- Geoffroy AndrieuxGAGeoffroy Andrieux
- Franziska E. MarquardFMFranziska E. Marquard
- Anna-Sophia BaurABAnna-Sophia Baur
- Anna-Verena StellASAnna-Verena Stell
- 9 April 2026
- journal article
- Published by American Society of Hematology in Blood
- Vol. 147 (15) , 1763-1778
Abstract
Acute graft-versus-host disease (aGVHD) is a major cause of death after allogeneic hematopoietic cell transplantation, and patients with steroid-refractory aGVHD have a dismal prognosis. We have previously shown that the enteroendocrine hormone glucagon-like peptide-2 has tissue regenerative activity in the lower gastrointestinal tract in mice and patients with steroid-refractory aGVHD. Here, we explored the tissue protective effect of the enteroendocrine hormone gastrin for aGVHD of the stomach. We observed that aGVHD caused a loss of gastrin-producing G-cells and parietal cells (PCs) and an increase in pH in the stomach, and allogeneic T cells had infiltrated the stomach wall. Pentagastrin treatment of aGVHD mice rescued the loss of PCs, normalized the pH in the stomach, increased stomach stem cell marker expression and abundance of LGR5+ cells. Gastrin also increased the viability of stomach and small intestine organoids in vitro. Compared with wild-type mice, Gast−/− mice experienced more severe aGVHD in the intestine and liver, which was rescued by pentagastrin treatment. In patients developing aGVHD, low gastrin levels in stomach biopsies were connected to reduced survival. Moreover, gastrin expression in the stomach correlated with aGVHD severity and tissue damage scores in independent patient cohorts. This study delineates the protective role of gastrin in aGVHD of the stomach in mice and patients and provides a rationale for the therapeutic use of pentagastrin in a clinical trial of patients with aGVHD.Keywords
This publication has 45 references indexed in Scilit:
- Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and OutcomesTransplantation and Cellular Therapy, 2022
- Hypergastrinemia Expands Gastric ECL Cells Through CCK2R+ Progenitor Cells via ERK ActivationCellular and Molecular Gastroenterology and Hepatology, 2020
- Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cellsNature Medicine, 2018
- Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regenerationNature, 2015
- The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective ReviewDigestive Diseases and Sciences, 2015
- Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damageNature Medicine, 2014
- Lgr5+ Stem Cells Are Indispensable for Radiation-Induced Intestinal RegenerationCell Stem Cell, 2014
- Interleukin-22 Protects Intestinal Stem Cells from Immune-Mediated Tissue Damage and Regulates Sensitivity to Graft versus Host DiseaseImmunity, 2012
- Graft-versus-host disease is enhanced by extracellular ATP activating P2X7RNature Medicine, 2010
- Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effectTransplantation and Cellular Therapy, 2003